Ann LaCasce, MD, MMSc

    Ann LaCasce, MD, MMSc

    Associate Professor of Medicine, Lymphoma Program, Dana-Farber Cancer Institute
    • You Make the Call: Should this patient with DLBCL receive rituximab maintenance after R-CHOP? Wednesday, July 1st, 2020

      This month Ann S. LaCasce, MD, MMSc, discusses whether a patient with high-risk DLBCL should receive rituximab maintenance after R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) or autologous transplantation. And don't forget to check out next month's clinical dilemma - send in your responses for a chance to win an ASH Clinical News-themed [...]

    • 200 Years of Hodgkin Lymphoma Friday, November 15th, 2019

      This year’s ASH Education Program features a look at the progress that has been made in the two centuries since Thomas Hodgkin entered medicine. Here, session chair Ann LaCasce, MD, previews the discussion, including novel therapeutic approaches and their economic impact.